Report highlights importance of equal medicine access across Europe

19 April 2024

Former Italian Prime Minister Enrico Letta has stressed the importance of access to medicines in a report on what is next for Europe’s single market.

Equity of medicine access, sustainable pricing and procurement models for supply and European Union (EU)-wide funds for domestic investments in medicine manufacturing are all encouraged in the Report on the Future of the Single Market.

The Letta Report calls on the EU to strengthen the market to improve access to medicines, building on the EU Pharmaceutical Strategy. Timely patient access to more generic and biosimilar medicines should be priorities in the legislative review and in the next institutional cycle.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK